ASND
Ascendis Pharma A/S
NMS
$218.06
+2.46
(+1.14%)
Pullback · -0.53σ
132-Day TAO Zones
21 EMA
+1 ATR
+2 ATR
−2 ATR
—
O —
H —
L —
C —
—
—
Key statistics
Mkt cap
$14.3B
P/E ttm
25.0
Fwd P/E
20.0
Beta
—
Day range
$218.06
52w range
$188.08 – $250.74
Avg vol
0.6M
RSI(2)
81.4
ROE
332.7%
Net mgn
57.3%
FCF mgn
13.7%
Debt/Eq
1.84
Div yld
—
Sector
Healthcare
Industry
Biotechnology
Next earn
2026-04-30
Matrix setup grades
Long
—
score 18 · tech 18 / 80 · support 0 / 20
above KC1 lower, -0.49 ATR from EMA21 · no notable pattern
- · RSI hook from oversold (44)
- · Aligned with weak uptrend
Short
—
score 24 · tech 24 / 80 · support 0 / 20
below KC1 upper, -0.49 ATR from EMA21 · shooting star
- · Shooting star — long upper wick rejection
Valuation & accounting
DCF + multiples · long-term lensIntrinsic (DCF)
$100.45
Fair-value range
$34.97 – $158.40
Margin of safety
-105%
Verdict
Overvalued
Accounting quality
Weak
- ✓ Goodwill 0% of assets (organic growth)
- ✓ Gross margin 89% (pricing power)
- ✓ Net margin 57%
- ⚠ Debt exceeds cash
- ⚠ Quick ratio 0.67 (fragile)
- ⚠ Stock comp 16% of revenue (heavy dilution)
Price implies ~38% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
Options · swing
See more →
CALL
$220
2026-07-17
$12.30
PUT
$220
2026-07-17
$13.80
Insider activity
See more →No Form 4 filings in the last 30 days.
Earnings
See more →- Last reported
- 2026-05-07
- EPS (act / est)
- 9.75 / -0.08
- Surprise
- +12287.5%
- Next report
- 2026-04-30
About
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypopara…